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This article is one of ten reviews selected from the
Annual Update in Intensive Care and Emergency
medicine 2016. Other selected articles can be found
online at http://www.biomedcentral.com/collections/
annualupdate2016. Further information about the
Annual Update in Intensive Care and Emergency
Medicine is available from http://www.springer.com/
series/8901. The composition of 0.9 % saline was first mentioned by
Jakob Hamburger in the 1890s. It is unknown how 0.9 %Background
“She filled his ancient veins with rich elixir. As he
received it … his wasted form renewed, appeared in
all the vigor of bright youth, no longer lean and
sallow, for new blood coursed in his well‐filled veins”
(Publius Ovidius Naso, Metamorphoses Book VII –
The Story of Medea and Jason, 8 AD).
Our desire to find solutions that rejuvenate and resus-
citate is captured in the story of Medea revitalizing
Jason’s elderly father by filling his veins with a specially
prepared elixir. Although no such elixir exists, intraven-
ous fluids are an integral component of the multimodal
resuscitation strategy used in medicine. Intravenous
fluids were first administered over 180 years ago and
despite their widespread use there remains uncertainty
about their relative safety and efficacy.
Worldwide, there is variation in the prescribing of re-
suscitative intravenous fluids and the preferred choice of
fluid appears to be based on local customs, marketing,
fluid costs and availability [1]. The majority of intraven-
ous fluids were introduced into clinical practice during
an era where they did not undergo the same scrutiny as
other drugs. Hence, there is a paucity of research in this
area and only recently has there been an increase in
academic interest in the comparative effectiveness of
different intravenous fluids.* Correspondence: sumeet.reddy@mrinz.ac.nz
1Medical Research Institute of New Zealand, 6021 Wellington, New Zealand
Full list of author information is available at the end of the article
© 2016 Reddy et al.Here, we review the composition of different crystal-
loid fluids, potential pathophysiological responses fol-
lowing crystalloid fluid infusion, evidence from animal
studies, observational studies, and interventional studies
comparing crystalloid fluids, and suggest future direc-
tions for research on the comparative effectiveness of
various crystalloid fluids.Unbuffered/unbalanced crystalloids
saline became known as ‘normal saline’; however, use of
term ‘normal’ may have contributed to the widespread
acceptance of 0.9 % saline into clinical practice. Despite
being referred to as ‘normal’, 0.9 % saline is not physiolo-
gically ‘normal’. First, 0.9 % saline has a higher chloride
concentration than plasma. Second, 0.9 % saline has a dif-
ferent strong ion difference (SID) to plasma. According to
the Stewart physiochemical approach to describing acid‐
base balance, fluid pH is in part determined by the SID,
which is the sum of the strong cation concentrations in
the solution (e.g., sodium, potassium, magnesium), minus
the sum of the strong anion concentrations in the solution
(e.g., chloride and lactate). The SID of the extracellular
fluid is approximately 40mEq/l, whereas the SID of 0.9 %
saline is zero. Following an infusion of 0.9 % saline there is
a net decrease in the plasma SID resulting in a metabolic
acidosis.
0.9 % saline is often thought of as a relatively hyper-
tonic solution because the sum of its osmotically active
components gives a theoretical in vitro osmolality of
308mosmol/kg H2O (154mmol/l sodium plus 154mmol/
l chloride). However, 0.9 % saline is more accurately re-
ferred to as an isotonic solution as its constituents – so-
dium and chloride – are only partially active, with an
osmotic coefficient of 0.926. The calculated in vivo osmo-
lality (tonicity) of saline is 285 mosmol/kgH2O, which is
the same as plasma osmolality (tonicity).Buffered/balanced crystalloids
Sydney Ringer’s in vitro experiments in the 1880s on the
influence of crystalloid fluid composition on cardiac
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of the addition of other inorganic constituents to sodium
chloride solutions. Alexis Hartmann further modified
Ringer’s solution through the addition of sodium lactate
to act as a buffering agent in an effort to combat acidosis
in dehydrated pediatric patients.
Unlike 0.9 % saline, the available buffered crystalloid
solutions contain physiological or near physiological
amounts of chloride. One of the key differences between
0.9 % saline and buffered/balanced crystalloids is the
presence of additional anions, such as lactate, acetate,
malate and gluconate, which act as physiological buffers
to generate bicarbonate. Further, buffered fluids, such as
Hartmann’s solution and Ringer’s lactate, have near
physiologically effective in vivo SIDs of 27 and 29mEq/l,
respectively. In contrast, Plasma‐Lyte 148® has an effect-
ive SID in vivo of 50 mEq/l. Despite the fact that buff-
ered crystalloid fluids are designed to better mimic the
composition of human plasma, no perfectly balanced or
physiologically ‘normal’ crystalloid fluid is currently
available (see Table 1).
Historically, sodium acetate was used during hemo-
dialysis as an alternative to bicarbonate because of the
incompatibility of bicarbonate with solutions containing
calcium and magnesium salts. Early evidence suggested
that sodium acetate solution was effective in restoring
blood pH and plasma bicarbonate in patients sufferingTable 1 Characteristics of common crystalloid solutions compared t






Sodium (mmol/l) 136–145 154 129 130
Potassium (mmol/l) 3.5–5.0 5 4
Magnesium (mmol/l) 0.8–1.0
Calcium (mmol/l) 2.2–2.6 2.5 3
Chloride (mmol/l) 98–106 154 109 109
Acetate (mmol/l)
Gluconate (mmol/l)
Lactate (mmol/l) 29 28
Malate (mmol/l)
eSID (mEq/l) 42 27 28
Theoretical osmolarity
(mosmol/l)




287 286 256 256
pH 7.35–7.45 4.5–7 5–7 5.0–7
a Freezing point depression
Plasma‐Lyte 148 manufactured by Baxter Healthcare, Toongabie, NSW, Australia
Ringer’s Lactate manufactured by Baxter Healthcare, Deerfield, IL, USA
Hartmann’s solution manufactured by Baxter Healthcare, Toongabie, NSW, Australia
Ionosteril manufactured by Fresenius Medical Care, Schweinfurt, Germany
Sterofundin ISO manufactured by B. Braun Melsungen AG, Melsungen, Germanyfrom metabolic acidosis [2]; however, a more recent
study suggested that acetate was associated with hemo-
dynamic instability, vasodilatation and negative inotropic
affects in patients undergoing high volume renal replace-
ment therapy (RRT) [3]. Concern about the potential for
myocardial depression with acetate is supported by stud-
ies suggesting that acetate decreases myocardial contrac-
tilityand blood pressure in dogs [4] and impaired
contractile function in anisolated perfused rat heart
model [5]. Even the small quantity of acetate present in
various dialysis fluids (usually 35 mmol/l) can result in
plasma acetate concentrations of 10 to 40 times the
physiological level (50 to 100 μmol/l) [6]. Use of acetated
solutions as acircuit prime for cardiac patients under-
going cardiopulmonary bypass (CPB) also results in
short‐livedsupra‐physiological concentrations of acet-
ate; however, it is not clear if these have any adverse
clinical effects [7].
Despite these potential concerns, there are several the-
oretical advantages of using acetated solutions compared
tolactate‐containing crystalloids. Acetate is metabolized
widely throughout the body, is not reliant entirely on
hepaticmetabolism and is metabolized more rapidly than
lactate [8]. A canine study showed that acetate metabol-
ism was well‐preserved in profound shock while lactate
metabolism was significantly impaired [9]. Acetate me-






















270 Not stated 271
6.9–7.9 5.1–5.9 4–8
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tate can be converted to glucose via gluconeogenesis
resulting in hyperglycemia [10]. Acetate turnover shows
no age‐related differences [11], and acetate may protect
against malnutrition by replacing fat as anoxidative fuel
without affecting glucose oxidation, or causing hypergly-
cemia [10].
Little is known about the clinical effects of gluconate.
Gluconate is largely excreted unchanged in the urine
(80 %). In a recent Phase II evaluation of an acetate/
gluconate‐based buffered solution (Plasma‐Lyte 148®)
versus abicarbonate buffered crystalloid fluid for CPB
circuit priming, Plasma‐Lyte 148® was associated with an
immediate increase in unmeasured anions of > 10mEq/l
(presumably acetate and/or gluconate), with residual ele-
vations still present just prior to CPB cessation [12]. The
clinical significance of elevated gluconate and/or acetate
levels remains unclear in this setting.
Hartmann’s solution or Ringer’s lactate are hypotonic
solutions with a calculated in vivo osmolality (tonicity)
of approximately 254 mOsmol/kgH2O. Perioperative ad-
ministration of hypotonic fluids can represent a signifi-
cant free water load that may not be easily excreted in
the presence of the high anti‐diuretic hormone concen-
trations commonly associated with physiological stress.
Failure to excrete water in a timely fashion may result in
postoperative positive fluid balance, edema, and weight
gain. Hypotonic fluids are also contraindicated in pa-
tients with or at risk of cerebral edema.
In addition to differences in buffering agents, buffered
solutions also vary in the presence and concentration of
ancillary cations (sodium, potassium, calcium, magne-
sium), which means they are not biologically equivalent.
Hartmann’s solution contains 2 mmol/l of calcium and is
contraindicated with blood or blood‐related products
due to concerns about precipitation and the possibility
of coagulation and clot formation. A recent warning has
been issued about mixing calcium‐containing solutions,
including Hartmann’s solution or Ringer’s lactate, with
ceftriaxone causing the formation of the insoluble ceftri-
axone calcium salt [13].
Although some authors have argued that hyper-
chloremia secondary to 0.9 % saline is a benign and
self‐limiting phenomenon, there is some evidence that
hyperchloremia is independently associated with adverse
clinical outcomes [14]. The biological plausibility that
0.9 % saline may affect renal function is supported by a
cross‐over study of 12 volunteers that reported signifi-
cantly higher serum chloride levels, reduced renal artery
blood velocity and reduced renal cortical tissue perfusion
in subjects who received 2 l of 0.9 % saline over 1 h com-
pared to those that had received Plasma‐Lyte 148® [15].
This study also found that although 0.9 % saline and
Plasma‐Lyte 148® expanded the intravascular volume tothe same degree, 0.9 % saline expanded the extracellular
fluid volume significantly more than did Plasma‐Lyte 148®
meaning that 0.9 % saline may be more likely to result in
fluid overload and interstitial edema.
Experimental research has identified possible hema-
tological and gastrointestinal pathways that may be im-
paired with the use of 0.9 % saline. Ex vivo testing of
diluted whole blood reported that dilution with Ringer’s
lactate resulted in less impairment in thrombin gener-
ation and platelet activation when compared to 0.9 %
saline [16]. A swine study reported that metabolic acid-
osis significantly impaired gastropyloric motility by redu-
cing pyloric contraction amplitude, which results in
delayed gastric emptying or gastroparesis [17].
Animal studies comparing 0.9 % saline to
buffered crystalloid fluids
Recently, Zhou et al. reported decreased rates of acute
kidney injury (AKI) and improved survival in rats receiv-
ing Plasma‐Lyte® compared to 0.9 % saline in an animal
model of sepsis [18]. In this experiment, 60 rats were
randomized to receive 0.9 % saline or Plasma‐Lyte® for
4 h (10 ml/kg for the first hour and 5ml/kg over the next
3 h) after 18 h of cecal ligation and puncture. Rats that
received 0.9 % saline had higher rates of AKI (100 % vs.
76 %, p < 0.05) and significantly worse AKI severity
based on the Risk, Injury, Failure, Loss of kidney func-
tion, End‐stage kidney disease (RIFLE) criteria creatinine
definitions (RIFLE‐I or F: 83 % vs. 28 %, p < 0.001).
Histopathological and biomarkers (urine cystatin C and
urine neutrophil gelatinase‐associated lipocalin) of AKI
were also significantly worse in rats that received 0.9 %
saline compared to rats that received Plasma‐Lyte®.
The largest animal study comparing 0.9 % saline versus
buffered fluid was a swine model of hemorrhagic shock
that randomized 116 pigs to crystalloid fluid replacement
at different percentages of replacement (0.9 % saline at
14 % replacement of blood loss; 0.9 % saline at 100 % re-
placement of blood loss; 0.9 % saline at 300 % replacement
of blood loss; Ringer’s lactate at 300 % replacement of
blood loss; Plasma‐Lyte A® at 300 % replacement of blood
loss; Plasma‐Lyte R® at 300 % replacement of blood loss)
[19]. In a comparison of the different 300 % treatment
groups, a significant difference was found in survival at
24 h in pigs that received Ringer’s lactate (67 %) compared
to Plasma‐Lyte A® (30 %). No difference was found in sur-
vival rates in 0.9 % saline (50 %) or Plasma‐Lyte R® (40 %)
groups.
Observational studies comparing 0.9 % saline to
buffered crystalloid fluids
The majority of evidence demonstrating potential ad-
verse clinical effects with the use of 0.9 % saline com-
pared to buffered crystalloids originated from recent
Reddy et al. Critical Care  (2016) 20:59 Page 4 of 9observational studies in critically unwell and surgical pa-
tients [20–22]. In a single center, open‐label, sequential
6‐month study of 1533 critically ill patients, the change
from standard chloride‐liberal fluids (0.9 % saline, 4 %
succinylate gelatin or 4 % albumin) to chloride‐restrictive
fluids (Hartmann’s solution, Plasma‐Lyte 148® and 20 % al-
bumin) was associated with a significant decrease in the
risk of developing RIFLE‐defined AKI (odds ratio [OR]
0.52, 95 % CI 0.37–0.75, p < 0.01) and requirements for
RRT while in the intensive care unit (ICU) (OR 0.52,
95 % CI, 0.33–0.81, p = 0.004) [20]. No difference between
groups was found in hospital mortality and hospital or
ICU length of stay. A recently published extended analysis
over the 12 months before and after the strategy change,
which included 2994 patients, reported persistently lower
rates of AKI according to the Kidney Disease: Improving
Global Outcomes (KDIGO) creatinine definitions and
decreased requirements of RRT [23]. Because multiple
changes in fluids occurred simultaneously in this ob-
servational study it is not possible to determine what
component of the fluid change strategy (if any) was
responsible for the observed changes.
The two largest studies that have assessed the effects of
buffered versus unbuffered crystalloid fluid were retro-
spective observational studies with patient data collected
from centralized health‐economic databases [21, 22]. The
most recent study was conducted in non‐surgical,
adult patients with the International Classification of
Disease, Ninth Edition Clinical Modification (ICD‐9‐
CM) codes for sepsis who were receiving vasopressors
in the ICU by day two, and had received three con-
secutive days of antibiotics and had had a blood cul-
ture [21]. In total 53,448 patients were identified
from 360 hospitals over five years. Of this cohort,
only 3365 patients (6.4 %) had received some “balanced
fluids” during their first two hospital days. This sample
was compared with a propensity‐matched group of 3365
patients who had “not received balanced fluids” (received
either 0.9 % saline or 5 % dextrose). Patients who had re-
ceived balanced fluids had a significantly lower in‐hospital
mortality (19.6 % vs. 22.8 %; relative risk [RR] 0.86, 95 %
CI 0.78–0.94, p = 0.001) compared to the group that had
not received balanced fluids. No difference was found be-
tween groups in acute renal failure (defined by ICD‐9‐CM
codes), need for dialysis and hospital or ICU length of
stay. The vast majority of patients in the balanced group
had received a mixture of intravenous fluids and it was re-
ported that less than 1 % of patients in the balanced fluid
group had exclusively received balanced fluids. On further
analysis, patients were stratified by the proportion of
balanced to unbalanced fluid they had received. The rela-
tive risk of in‐hospital mortality was progressively lower
among patients who received a greater proportion of bal-
anced fluid.A similar retrospective study was conducted in adult
patients who had undergone non‐traumatic, open, gen-
eral surgical abdominal operations who had exclusively
received either 0.9 % saline or a balanced fluid (defined
as a calcium‐free buffered fluid: Plasma‐Lyte 148® or
Plasma‐Lyte A®) on the day of surgery [22]. In total
271,189 patients from approximately 600 hospitals had
received fluids on the day of surgery. Of these patients,
30,994 received 0.9 % saline and 926 received balanced
fluid. Propensity matching was used to mitigate for base-
line group imbalances, which included a significantly
higher proportion of minorities, less commercial insur-
ance, greater proportion of patients from non‐teaching
hospitals, greater proportion of admissions via the emer-
gency department and significantly higher rates of co‐
morbidities (based on ICD‐9‐CM codes), such as renal
failure, diabetes and congestive heart failure in patients
that had exclusively received 0.9 % saline. On matched
analysis, patients who exclusively received balanced fluid
had a decreased risk of major complications (OR 0.79,
95 % CI 0.66–0.97, p < 0.05) including need for blood
transfusion (1.8 % vs. 11.5 %, p < 0.001) and need for
dialysis (1.0 % vs. 4.8 %, p < 0.001). However, those in
the balanced fluid group had higher rates of minor
gastrointestinal complications (OR 1.45; 95 % CI 1.17–
1.79, p < 0.05) and longer hospital lengths of stay (6.4 vs.
5.9 days, p < 0.001).
Overall, existing data from observational studies
suggest that the use of high chloride, unbuffered crys-
talloid fluid may be associated with major complica-
tions following surgery and increased mortality in
critically ill patients with sepsis. However, due to the
retrospective nature of these studies and potential for
unmeasured confounding, it is not possible to estab-
lish whether using buffered crystalloid fluid instead of
0.9 % saline is beneficial or harmful on the basis of
observational studies.
Interventional studies comparing 0.9 % saline to
buffered crystalloid fluids
Until 2015, all interventional studies comparing 0.9 %
saline to buffered crystalloid had a small sample size
(n < 100) and focused primarily on short term physio-
logical or biochemical outcomes (see Table 2). A sys-
tematic review and meta‐analysis published in 2014
identified 28 prospective, randomized controlled trials
with at least 20 adult participants that had compared
the effects of different crystalloid fluids [24]. Twenty‐
three studies that explored acid‐base balance reported
that 0.9 % saline was associated with decreased serum
pH, elevated serum chloride levels and decreased bi-
carbonate levels. In 11 studies that explored renal
function, based on urine volume or serum creatinine,
no significant difference was found between fluids. In
Table 2 Summary of the key interventional clinical studies that have compare 0.9 % saline to buffered crystalloid fluid in adult
patients




Multicentre, double-blind, cluster randomised, double crossover trial
comparing 0.9 % saline with Plasma-Lyte 148®; n= 2262
• There was no significant difference between group
in rates of AKI or AKI requiring RRT
• There was no significant difference between
groups in survival to day 90
Smith et al.
2015 [28]
Single centre, double-blind RCT comparing 0.9 % saline with
Plasma-Lyte A® in critically ill trauma patients; n=18
• Patients receiving 0.9 % saline had significantly
lower serum chloride and bicarbonate concentration
• Patients receiving Plasma-Lyte A® had a quicker
fibrin build up and cross linking (α angle) at 6 hours after infusion
• No difference between groups in coagulation tests
or blood products received at 6 hours
Young et al.
2014 [29]
Single centre, double-blind RCT comparing 0.9 % saline with
Plasma-Lyte A® in patient presenting to ED with severe acute
trauma; n=46
• Patients receiving 0.9 % saline had an increase in
serum chloride concentration and decrease in serum pH
• No significant differences in mortality hospital




Single centre, open label RCT comparing 0.9 % saline with Ringer’s
lactate in patients with severe dehydration secondary to choleriform
diarrhea; n=40
• Patients receiving 0.9 % saline had lower serum pH
at 2 and 4 hours




Single centre, double-blind RCT comparing either 0.9 % saline,
Ringer's lactate or Plasma-Lyte® in patients presenting to ED with
dehydration; n= 90
• Patients receiving 0.9 % saline had a significantly
lower serum pH and lower serum bicarbonate
concentration
• No difference between groups in chloride,
potassium, or sodium concentrations
Van Zyl et al.
2012 [32]
Multicentre, double-blind RCT of Ringer’s lactate versus 0.9 %
saline in patients presenting to ED with diabetic ketoacidosis;
n=54
• There was no significant difference between
groups in time interval for correction of acidosis
• Patient receiving 0.9 % saline a significantly shorter
time to lower blood glucose
• No difference between groups in hospital length of stay
Mahler et al.
2011 [33]
Single centre, double-blind RCT comparing either 0.9 % saline with
Plasma-Lyte A® in patients presenting to ED with diabetic
ketoacidosis; n= 45
• Patients receiving 0.9 % saline had significantly




Multicentre, open label RCT comparing 0.9 % saline with Ringer’s
lactate in patients diagnosed with acute pancreatitis; n=40
• Patients receiving Ringer’s lactate had lower rates
of SIRS and lower CRP concentration at 24 hours
• No difference between groups in development of
complications or hospital length of stay
Cho et al.
2007 [35]
Multicentre, single-blind RCT of Ringer’s lactate versus 0.9 %
saline in patients presenting to ED with rhabdomyolysis; n=28
• Patients receiving 0.9 % saline had a significantly
higher serum chloride and sodium concentration
and lower serum pH
• There was no significant difference between






Prospective phase 4, single centre blinded study investigating the
safety and efficacy of using 0.9 % saline with Plasma-Lyte® 148 as
fluid therapy in adult patients undergoing major surgery; n=1100
• There was no significant difference between
groups in rates of AKI
• There were no significant difference between
groups in the development of postoperative
complications or length of hospital stay
• Patients who received 0.9 % saline developed a




Single centre, open label RCT comparing 0.9 % saline with Elomel
Isoton®(low chloride, acetate buffered crystalloid) in patients
undergoing renal transplantation; n=150
• Significantly more patients receiving 0.9 % saline
required intra-operative inotrope support
• Patients receiving 0.9 % saline had a significantly
lower base excess and higher serum chloride
concentration
• No difference between groups in post-operative
urine output, creatinine, blood urea nitrogen or
need for RRT
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Single centre, open label RCT comparing 0.9 % saline with
Plasma-Lyte® in patients undergoing spinal surgery; n=50
• Patients receiving 0.9 % saline had lower pH, base
excess, and bicarbonate concentration and higher
serum chloride concentration
• Patients receiving Plasma-Lyte® had significantly
higher urine output
• No difference between groups in rotation




Single centre, open label RCT comparing 0.9 % saline with
Sterofundin® ISO patients undergoing neurosurgery (low chloride,
acetate buffered crystalloid); n=30
• Patients receiving 0.9 % saline had a significantly




Single centre, blinded RCT comparing either 0.9 % saline with
Plasma-Lyte® in patients undergoing renal transplantation; n= 60
• Patients receiving 0.9 % saline had lower pH and
base excess values
• No difference between groups in post-operative
urine output, creatinine or need for RRT
Modi et al.
2012 [40]
Single centre, double-blind RCT comparing 0.9 % saline with Ringer's
lactate in patients undergoing renal transplantation; n= 74
• Patients receiving 0.9 % saline had lower serum pH and
base excess values
• No difference between groups in post-operative
urine output or creatinine
Heidari et al.
2011 [41]
Single centre, double-blind RCT comparing 0.9 % saline with Ringer’s
lactate and 5% saline in patients undergoing lower abdominal
surgery; n=90
• A higher proportion of patients that had received
0.9 % saline had experienced vomiting 6 hours
post-operatively
Hadimioglu
et al. 2008 [42]
Single centre, double-blind RCT comparing either 0.9 % saline,
Ringer's lactate or Plasma-Lyte® in patients undergoing renal
transplantation; n= 90
• Patients receiving 0.9 % saline had an increase in
serum chloride concentration and decrease in serum pH
• Patients receiving Ringer’s lactate had a
significantly increased serum lactate concentration
• There was no significant difference between in
postoperative creatinine or need for RRT
Khajavi et al.
2008 [43]
Single centre, double-blind RCT comparing 0.9 % saline with Ringer's
lactate in patients undergoing renal transplantation; n= 52
• Patient receiving 0.9 % saline had a significantly
lower serum pH and higher serum potassium
concentration at the end of the operation
Chin et al.
2006 [44]
Single centre, open label RCT comparing 0.9 % saline with Ringer’s
lactate, 0.9 % saline with dextrose 5 % in non-diabetic patients
undergoing elective surgery; n=50
• No difference between groups in serum urea,
sodium or potassium concentration
• Dextrose 5 % resulted in significant, albeit transient
hyperglycemia, even in non-diabetic patients
Karaca et al.
2006 [45]
Single centre, single-blinded RCT comparing 0.9 % saline with
Ringer’s lactate and 4 % gelatin polysuccinate in patients undergoing
transurethral prostatectomy under spinal anesthesia; n=60
• No difference between groups nausea, vomiting,
dizziness and post spinal hearing loss.
Chanimov
et al. 2006 [46]
Single centre, double-blinded RCT comparing 0.9 % saline with
Ringer’s lactate in patients undergoing Cesarean section; n=40
• No difference between groups in inotrope
requirements
• No significant differences in the Apgar scores at 1
and 5 min or infant well-being
O’Malley et al.
2005 [47]
Single centre, double blind RCT comparing 0.9 % saline with Ringer’s
lactate in patients undergoing renal transplantation; n=51
• Significantly more patients receiving 0.9 % saline
required intra-operative treatment for metabolic
acidosis and hyperkalemia
• No difference between groups in post-operative
urine output, creatinine or need for RRT
Takil et al.
2002 [48]
Single centre, open label RCT comparing 0.9 % saline with Ringer’s
lactate in patients undergoing spinal surgery; n=30
• Patients receiving 0.9 % saline had an increase in
serum chloride, sodium concentration and
decrease in serum pH
• No difference between groups in intraoperative
hemodynamic variables or hospital and ICU lengths of stay
Waters et al.
2001 [49]
Single centre, double-blind RCT comparing 0.9 % saline with Ringer’s
lactate in patients undergoing abdominal aortic aneurysm surgery;
n=66
• Patients receiving 0.9 % saline had an increase in
serum chloride, sodium concentration and
decrease in serum pH
• Patients receiving 0.9 % saline received a greater
volume of platelets
• No difference between groups in estimated blood
loss, postoperative complications, hospital and
ICU lengths of stay
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Table 2 Summary of the key interventional clinical studies that have compare 0.9 % saline to buffered crystalloid fluid in adult
patients (Continued)
Scheingraber
et al. 1999 [50]
Single centre, open label RCT comparing 0.9 % saline with Ringer’s
lactate in patients undergoing gynecologic surgery; n=24
• Patients receiving 0.9 % saline had an increase in
serum chloride concentration and decrease in
serum pH
Ramanathan
et al. 1984 [551]
Single centre, open label RCT comparing 0.9 % saline with Ringer’s
lactate, Ringer’s lactate with dextrose 5 % and Plasma-Lyte A®
in patients undergoing Cesarean section; n=60
• Patients receiving 0.9 % saline had an decrease in
serum pH
• No difference between groups in blood pressure or
inotrope requirements
AKI acute kidney injury, CRP C-reactive protein, ED emergency department, RCT randomized control trial, RRT renal replacement therapy, SIRS systemic
inflammatory response syndrome, The SPLIT trial 0.9 % Saline versus Plasma-Lyte 148® for Intensive Care Unit fluid Therapy trial, The SPLIT- Major Surgery trial
0.9 % Saline or Plasma-Lyte® 148 as fluid therapy in adult patients undergoing major surgery trial
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of red blood cells transfused, patients who had re-
ceived Ringer’s lactate required significantly less vol-
ume of red blood cells than those who had received
0.9 % saline (RR 0.42, 95 % CI 0.11–0.73). No differ-
ences were found between Ringer’s lactate and 0.9 %
saline in requirements for transfusion or operative
blood loss, except in an exploratory sub‐group ana-
lysis of “high‐risk” patients that showed increased
blood loss with the use of 0.9 % saline in patients
that were at increased risk of bleeding.
Based on the published evidence prior to 2014, the
National Institute for Health and Care Excellence (NICE)
guidelines on intravenous fluid therapy in adults in hos-
pital currently recommend the use of crystalloids that
contain sodium in the range 130–154mmol/l for fluid re-
suscitation [25]. However, the guidelines state that the
available evidence at the time of writing was limited and
of “poor” quality. Research todate has been in heteroge-
neous populations and has been underpowered to allow
for differences to be detected inclinically significant out-
come measures. The NICE committee specifically identi-
fied that research comparing balanced solutions to 0.9 %
saline for fluid resuscitation was a high priority.
The SPLIT program
The 0.9 % saline vs. Plasma‐Lyte 148® for intravenous
fluid therapy research program is an investigator‐initiated,
bi‐national collaborative research program investigating
the comparative effectiveness of 0.9 % saline versus a buff-
ered crystalloid as intravenous fluid therapy. Specific
details on the study design, methods of analyzing and
reporting of the research program have been published
previously [26]. At the time of writing, four of the six
planned studies in critically unwell and elective surgical
patients have been completed.
The largest study was the 0.9 % Saline versus Plasma‐
Lyte 148® for Intensive care fluid Therapy (SPLIT) trial.
The SPLIT trial was a multicenter, blinded, cluster ran-
domized, double crossover study that compared Plasma‐
Lyte 148® with 0.9 % saline as the routine ICU intravenous
fluid [27]. All ICU patients needing crystalloid fluidtherapy were eligible to be included. Patients who were on
dialysis, expected to require RRT within six hours and pa-
tients admitted to the ICU solely for organ donation or
for palliative care were excluded. In total, 2262 patients in
four New Zealand tertiary ICUs over a 28‐week period
were enrolled and analyzed, with 1152 patients assigned
to receive Plasma‐Lyte 148® and 1110 assigned to receive
0.9 % saline. The two groups of patients had similar ad-
mission diagnoses and baseline characteristics. There were
no differences between patients who received Plasma‐Lyte
148® compared to 0.9 % saline in rates of AKI (9.6 % vs.
9.2 % [difference 0.4 %, 95 % CI −2.1 %–2.9 %; RR 1.04,
95 % CI 0.80–1.36, p = 0.77]) or requirements for RRT
(3.3 % vs. 3.4 % [difference 0.1 %, 95 % CI −1.5 %–1.4 %;
RR 0.96, 95 % CI 0.62–1.50, p = 0.91]). There were also
no significant differences in need for mechanical ventila-
tion, readmission to the ICU, ICU length of stay or in hos-
pital mortality.
Two single‐centered, pilot, nested cohort studies were
also conducted in patients enrolled in the SPLIT trial.
The first of these studies evaluated 251 adults who had
undergone cardiac surgery: 131 were allocated to Plasma‐
Lyte 148® and 120 were allocated to 0.9 % saline. No differ-
ence was found between groups in postoperative chest
drain output or in the proportion of patients developing a
major postoperative complication (death, myocardial in-
farction, new focal neurological deficit or renal failure re-
quiring dialysis). However, fewer patients in the 0.9 %
saline group required blood products (packed red blood
cells, fresh frozen plasma, platelets or cryoprecipitate)
compared to patients in the Plasma‐Lyte 148® group
(18.3 % vs. 30.5 %, p = 0.03). The second nested cohort
study compared gastrointestinal feeding intolerance in 69
patients (35 assigned to receive Plasma‐Lyte 148® and 34
to receive 0.9 % saline) expected to require mechanical
ventilation for greater than 48 h and receiving enteral nu-
trition exclusively by a nasogastric tube. Despite no differ-
ence between groups in the proportion of patients with
gastrointestinal feeding intolerance (defined as high
gastric residual volume, diarrhea or vomiting while re-
ceiving nasogastric feeding in the ICU), a significantly
lower proportion of patients in the Plasma‐Lyte 148®
Reddy et al. Critical Care  (2016) 20:59 Page 8 of 9group developed high gastric residual volumes (11.4 %
vs. 32.4 %, p = 0.04).
Finally, a prospective single center blinded study inves-
tigated the safety and efficacy of using 0.9 % saline or
Plasma‐Lyte® 148 as fluid therapy in adult patients
undergoing major surgery. Trial fluid was used intraop-
eratively and postoperatively for three consecutive days.
Inclusion criterion included patients undergoing surgery
of at least two hours duration and requiring at least one
overnight stay. Patients with end‐stage renal disease and
those undergoing liver or renal transplantation were ex-
cluded. The primary outcome measure was the propor-
tion of patients with either acute kidney injury or failure
based on creatinine levels in accordance with RIFLE‐
criteria during the index hospital admission. Intraop-
eratively, there was 100 % compliance with the trial
protocol. A total of 746 patients received Plasma‐Lyte
148® and 634 patients received 0.9 % saline. Patients in
both groups had similar baseline characteristics with re-
spect to age, sex, body mass index, American Society of
Anesthesiologists (ASA) status, types and number of co-
morbidities, duration and types of surgery. The median
amount of trial fluid received was greater in the Plasma‐
Lyte 148® group: 2000ml (interquartile range [IQR] 1000,
2000) vs. 1925ml (1000, 2000) in the 0.9 % saline group
(p = 0.007). Patients receiving 0.9 % saline developed a
transient hyperchloremic metabolic acidosis on postopera-
tive Day 1 compared to patients receiving Plasma‐Lyte
148®. Postoperatively, there were no differences in the inci-
dence of AKI between the groups: 52 (10.9 %) patients in
the Plasma‐Lyte 148® group developed postoperative AKI
compared to 59 (9.3 %) patients in the 0.9 % saline group
(p = 0.41, 95 % CI 0.6–1.2). Patients who developed AKI
were older, had larger volumes of fluid both intraoperatively
and on postoperative Day 1, and had greater fluid balances
intraoperatively and on postoperative Day 1. There were
no differences in the development of postoperative com-
plications between the groups. Median lengths of stay
were similar between treatment groups: Plasma‐Lyte 148®
5.0 days (2.77–8.98) vs. 0.9 % saline 5.0 days (2.81–9.04).
Conclusion
Intravenous fluid therapy is a ubiquitous intervention in
critically ill patients. While pre‐clinical and observational
data raise the possibility that the choice of crystalloid
fluid therapy may affect patient‐centered outcomes,
there are currently no convincing data from interven-
tional studies demonstrating that this is the case. Recent
data suggest that 0.9 % saline and Plasma‐Lyte® 148 re-
sult in similar rates of renal complications when used
for fluid therapy in patients undergoing major surgery
and in ICU patients. Further large randomized con-
trolled trials are needed to assess the comparative effect-
iveness of 0.9 % saline and balanced/buffered crystalloidsin high‐risk populations and to measure clinical out-
comes such as mortality. Moreover, given the widespread
use of a range of balanced/buffered crystalloids in current
clinical practice, high quality studies comparing the vari-
ous buffered crystalloids available are also needed.
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